Edition:
United Kingdom

Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

3.73USD
15 Jan 2019
Change (% chg)

-- (--)
Prev Close
$3.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,816
52-wk High
$15.15
52-wk Low
$3.07

Latest Key Developments (Source: Significant Developments)

Aravive Presents Detailed Results Of Phase 1 Clinical Trial Of AVB-S6-500 At The 2018 EORTC-NCI-AACR Symposium
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Aravive Inc ::ARAVIVE PRESENTS DETAILED RESULTS OF PHASE 1 CLINICAL TRIAL OF AVB-S6-500 AT THE 2018 EORTC-NCI-AACR SYMPOSIUM.ARAVIVE INC - PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS DEMONSTRATED THAT AVB-S6-500 WAS WELL TOLERATED WITH AN ACCEPTABLE SAFETY PROFILE..ARAVIVE INC - THERE WERE NO SERIOUS ADVERSE EVENTS (AES) AND AVB-S6-500 WAS WELL TOLERATED ACROSS ALL DOSES.  Full Article

Versartis Q1 Loss Per Share $0.25
Tuesday, 8 May 2018 

May 8 (Reuters) - Versartis Inc ::VERSARTIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.25.CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $74.7 MILLION AS OF MARCH 31, 2018.  Full Article

Versartis reports Q3 loss $1.40/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Versartis Inc :Versartis reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.40.Q3 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article